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Deimination is the post-translational conversion of arginine residues to citrulline. It has been implicated as a
causative factor in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and more
recently, as a marker of neurodegeneration. We have investigated the effect of the post-translational
modiﬁcation of arginine residues on the structure of recombinant ovine prion protein. Deiminated prion
protein exhibited biophysical properties characteristic of the scrapie-associated conformer of prion protein
viz. an increased β-sheet secondary structure, congophilic structures indicative of amyloid and proteinase K
resistance which could be templated onto normal unmodiﬁed prion protein. In the light of these ﬁndings, a
potential role of post-translational modiﬁcations to prion protein in disease initiation or propagation is
discussed.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
The group of neurodegenerative diseases known as prion diseases
is frequently associated with the occurrence of plaques containing
prion protein (PrP) in an altered conformation, PrPSc. PrPSc is
purported to be infectious or at least, self-propagating [1]. We have
been interested in determining processes that might lead to a
conformational change in prion protein in vitro, as this might indicate
possible therapeutic strategies. Earlier studies indicated that oxidative
modiﬁcations to amino-acid residues had an impact on conformation
of recombinant PrP [2]. In this study we were interested in observing
the effect on the conformation of recombinant ovine PrP (rec ovPrP)
as a result of deimination.
Deimination is the conversion of arginine residues to citrulline and
has several implications for the structure of a protein. For example, the
ureido group of citrulline has a destabilising effect on protein structure
due to its urea-like properties; it can also bind Zn2+ and increases the
solubility of lipid hydrocarbon tails [3]. This destabilising effect of
citrulline has been seen on citrullination of several proteins including
ﬁlaggrin, trichohyalin, and myelin basic protein (MBP) and resulted in
a loss of the organised secondary structure of these proteins [4,5]. Loss
of the positive charge associated with deimination can also be
expected to have a large impact on structure. Basic proteins such as
MBP bind to negatively-charged lipid membranes via electrostatic
interactions so modiﬁcation of positive residues can disrupt this
interaction [6,7].
Peptidylcitrulline is produced from arginyl residues by the action
of a group of enzymes known collectively as peptidylarginine
deiminases (PADs). PADs catalyse the irreversible conversion of the
arginine guanidino group to an ureido group – a process known as
deimination – with concomitant loss of ammonia and the positive
charge on the residue [3]. This family of PAD enzymes is distinct from
other enzymes that produce citrulline such as nitric oxide synthase
and arginine deiminase because of the selectivity for peptidylarginine
over free arginine. There are several different classes of PAD. A
bacterial form has been identiﬁed in species such as Pseudomonas
aeruginosa and Porphyromonas gingivalis that allow the bacteria to
adapt to acidic environments by producing ammonia to lower the
local pH [8,9]. There are ﬁve known categories of mammalian PAD, all
requiring calcium ions for activity [10–14].
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In the case of prion protein, early amino acid sequencing data
reported the possibility of post-translationally modiﬁed arginyl
residues in the N-terminus of cellular PrP [1]. Gas-phase sequencing
of the N-terminus of Syrian hamster PrPC could not detect the
predicted arginine residues at position 3 (R25) in PrPC and positions 3
(R25) and 15 (R37) in PrPSc [15]. This suggested a modiﬁcation of
arginyl residues might be present. In addition, different forms of PrPSc
isolated from scrapie-infected mice cells were N-terminally
sequenced to conﬁrm their identity. It was noted that an unidentiﬁed
amino acid derivative of arginine was present at position 3 (R25),
which may facilitate a conformational change of PrPC to PrPSc [16].
In a review of mass spectrometric analysis of PrP, the theoretical
presence of citrulline instead of arginine in the N-terminus was
discussed [17].Themass of citrulline is 1 Damore than that of arginine.
Therefore, especially in crude, heterogenous preparations, peptides
containing the different residues are difﬁcult to distinguish from
unmodiﬁed, native peptides. Analysis of endoproteinase Lys-C and
tryptic digests of PrP could not conﬁrm the presence of any arginine
modiﬁcation, although the authors did not discuss the possibility of a
citrulline modiﬁcation per se it was acknowledged that a low level of
modiﬁcation, or a labile modiﬁcation would not be observed [18].
Trypsin cleaves proteins C-terminal of arginyl residues (unless the
subsequent residue is proline), and thus would not cleave if citrulline
were present instead. Although the tryptic peptide containing R25
gave the mass expected for arginine rather than citrulline, the authors
noted that the M+1 ion for the peptide was stronger than expected
and that a small fraction containing citrulline could have been present
[18–19].
In this study, we provide data on the effects of deimination of
recombinant ovine PrP including the ability to aggregate into large
insoluble amyloid ﬁbrils and plaques, an increased resistance to
protease digestion, a high β-sheet secondary structure content, and
the potential to template its properties onto unmodiﬁed rec ovPrP.
2. Materials and methods
2.1. Recombinant ovPrP (Met,25–233)
The protein used in this study was produced as described
previously [20]. Brieﬂy, full-length ovine protein was produced in E.
coli using a dual origin expression vector, and puriﬁed using two
sequential chromatographic steps, immobilised metal ion afﬁnity
chromatography and cation exchange chromatography. The protein
was puriﬁed under denaturing conditions from inclusion bodies and
refolded in non-reducing conditions by incubation with copper ions
followed by dialysis into sodium acetate storage buffer, pH 5.5. Mass
spectrometric analysis was used to conﬁrm the presence of full-length
protein and the oxidation of the two key cysteine residues.
2.2. Arginine modiﬁcation of ovPrP
Rec ovPrP was diluted in glycine–NaOH buffer (50 mM, pH 7.6),
containing calcium chloride (5 mM) and the deimination reaction
carried out using PAD at 0.66 U/ml. Samples were incubated at 52 °C
for 2 h or at times speciﬁed in the ﬁgures. The reactionwas stopped by
dialysis of the protein back into sodium acetate buffer (pH 5.5) to
remove the calcium prior to further analysis [3].
2.3. SDS-PAGE analysis
Protein samples were separated by SDS/PAGE under reducing
conditions using pre-cast 4–20% (w/v) tris–glycine gradient gels
(Invitrogen, Holland). Bands were visualised using the Coomassie®-
based protein stain, SimplyBlue™ (Sigma, UK) according to the
manufacturer's protocol. Gels were destained overnight, and then
dried at 80 °C for 1 h for storage. The gels displayed in this work are
representative of at least 2 experiments. Gel densitometry was carried
out using the Scion Image 1.63 software available at http://www.
ScionCorp.com.
2.4. Circular Dichroism spectroscopy
The CD spectra were acquired using a cell of 0.02 cm path length in
a spectropolarimeter (JASCO). Measurements were taken between
250 and 200 nm using a temperature-controlled cell, with a step
resolution of 0.1 nm and sensitivity of 10 mdeg. Twenty scans were
acquired and averaged for each sample. Spectra were normalised for
protein concentration and amino acid length to give a reading inmean
residue weight ellipticity [θmrw], degrees cm2 dmol−1.
2.5. Protease assays
Protein samples were incubated with proteinase K (PK) or trypsin
at a ﬁnal dilution, of 20 or 100 μg/ml, respectively. Incubations were
terminated at different times (default 1 h) by addition of PMSF to
10 mM to inhibit the protease and then boiled in SDS-PAGE sample
buffer at a 1:1 volume ratio. In some PK studies, copper sulphate
(1 mM) was also included in the protease reaction. Samples were
analysed by SDS-PAGE followed by Coomassie staining, as described
previously. β-breaker peptides (BACHEM, UK) were preincubated
with rec ovPrP (0.1mM ﬁnal concentration) for 2 hwith shaking, prior
to PK digestion and the results were analysed by SDS-PAGE.
2.6. Dye afﬁnity studies
Precipitates of modiﬁed rec ovPrP were spotted onto gelatin-
coated slides and stained with the dye Congo red (CR) using a
modiﬁcation of a previous protocol [21]. Stained protein was then
examined under a polarising microscope (Olympus, London, UK) for
birefringence. Soluble forms of the modiﬁed protein were incubated
with CR (25 μM) in phosphate buffer solution (0.1 M, pH 7.4) with
sodium chloride (150 mM), for 30 min at room temperature with
shaking, and the absorbance measured on a UV/Vis Spectrometer
Lambda 8 16 (PerkinElmer, Bedfordshire, UK) at 540 and 477 nm and
the amount of bound dye was calculated, following a previously
reported protocols [22]. ANS binding studies were carried out by
incubating rec ovPrP (0.1 mg/ml) with ANS in sample buffer for
10 min at 37 °C and the ﬂuorescence was measured on a Fluoroskan
Ascent (ThermoLabsystems, Basingstoke, UK) with excitation at
355 nm and emission 485 nm with a 20 ms integration time.
Thioﬂavin T (ThT) measurements were obtained by incubating rec
ovPrPwith the dye (10 μM) in glycine–NaOH buffer (50mM, pH 9), for
10 min before the ﬂuorescence was measured with excitation at
450 nm and emission 485 nm with a 20 ms integration time.
2.7. β-breaker peptides
A stock solution (1 mM) of the 13-residue peptide DAPAAPAG-
PAVPV, denoted iPrP13, was prepared in 50% (v/v) acetonitrile, 1%
(v/v) triﬂuoroacetic acid, and stored in aliquots at −80 °C until use.
The standard protocol for PK digestion of modiﬁed and unmodiﬁed rec
ovPrP was then followed, but including a preincubation of the protein
with iPrP13 (0.1 mM ﬁnal concentration) for 2 h at 37 °C with shaking,
and the results assayed by SDS-PAGE. During titrations of the iPrP13
peptide, the void volume was made up with corresponding volume of
a solution (1 mM) of a 10 residue peptide corresponding to the helix 1
region of ovPrP (DYEDRYYREN).
2.8. Fourier-transform infra-red (FTIR) spectroscopy
To investigate the structure of templated protein, FTIR spectrawere
recorded at room temperature on a Bruker Equinox 55 spectrometer
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equipped with a liquid nitrogen cooled mercury cadmium telluride
detector. The sample compartment was continuously purged with dry
air. For each sample, 256 interferograms were collected at a spectral
resolution of 2 cm−1. Sample and buffer spectra were measured
separately and subsequently subtracted using Protein Dynamics
software (Bruker). Thin ﬁlms of hydrated rec ovPrP were obtained
by depositing 200 μg of protein in a 30 μl volume on the crystal and
subsequent removal of excess water under a gentle N2 ﬂow.
2.9. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) of
modiﬁed rec ovPrP
Deiminated rec ovPrP was reduced, carbamidomethylated and
digested with trypsin. A 10% (w/v) stock solution of trypsin was
prepared in sodiumacetate buffer (50mM, pH5.5). Prior to use, thiswas
diluted 100-fold and incubated with deiminated and control samples of
rec ovPrP (0.75 mg/ml) at 37 °C with shaking for 1 h. The peptide
productswere analysedbyon-line LC-MS/MS. The tryptic peptideswere
separated on a reversed-phase column (0.1×100 mm; Vydac C18) with
a gradient of 0–30% (v/v) acetonitrile (containing 0.1% (v/v) formic
acid) over 30min, at a ﬂow rate of 500 nL/min. Peptideswere eluted via
a nanoelectrospray interface into a quadrupole time-of-ﬂight mass
spectrometer (Applied Biosystems). The mass spectral data were
matched to the protein sequence using Mascot software (Matrix
Science) and conﬁrmed by manual interpretation of MS/MS spectra.
3. Results
3.1. SDS-PAGE analysis and mass spectrometry of deiminated rec ovPrP
populations
To investigate the effects of conversion of arginyl residues to
citrulline, rec ovPrP was incubated with PAD for increasing time
periods (data not shown). The product was largely soluble, although
a small amount of an insoluble white precipitate formed with each
reaction. The latter increased with longer incubations and increasing
concentrations of rec ovPrP. After PAD treatment, the modiﬁed
protein sample could be resolved as a series of bands by
electrophoresis. The separate bands were expected to represent
distinct populations of modiﬁed protein, each with a different level
of modiﬁcation, and thus different charge, pI, and electrophoretic
mobility. Using rec ovPrP that separated as a single monomeric
species at 23 kDa on gel electrophoresis, a sample of PAD-treated
protein was prepared that ran as 3 bands between 23–25 kDa on
electrophoresis (Fig. 1).
The single band from the untreated protein and the three bands
from the treated samplewere excised from the electrophoresis gel and
digested with trypsin. The separate samples were then analysed by
reverse-phase HPLC-coupled mass spectrometry. Trypsin cleaves
peptide bonds C-terminal of lysine and arginine residues so
modiﬁcation of these residues may interfere with proteolysis.
Unmodiﬁed protein was readily digested by trypsin, whereas the
PAD-treated rec ovPrP was resistant to digestion. Increased concen-
trations of trypsin digested both modiﬁed and unmodiﬁed proteins
(data not shown). The extent of modiﬁcation, as judged by the
increase in apparent molecular weight, had little effect on the degree
of resistance to proteolysis, as each band remained at a similar
intensity throughout the incubation with trypsin.
Extracted ion chromatograms from LC-MS analysis of tryptic
peptides are shown in Fig. 2. Several peptide fragments were
identiﬁed in the untreated protein as those containing arginine
residues (Fig. 2): m/z values of 939.71 (R159YPNQVY165), 968.72
(Y166RPVDRY172), 1044.67 (Q222RESQAYY229), 1102.70 (R159YPNQ-
VYY166), 1428.62 (I142HFGNDYEDR151) and 1591.59 (I142HFGNDYE-
DRY152). On treatment of the protein with PAD, the intensity of the
signal from the peptides containing arginine decreased dramatically,
Fig.1. SDS-PAGE analysis of deimination of rec ovPrP by peptidylarginine deiminase (PAD). (a) Conversion of peptidylarginine to peptidylcitrulline. The ﬁgure details the deimination
of a positively-charged arginine residue to a neutral citrulline residue, such as that catalysed by PAD. The guanidino group of peptidylarginine is converted to an ureido group by
nucleophilic attack by the enzyme at the carbon of the guanidino groupwith concomitant protonation and loss of the imino group as ammonia. This is followed by nucleophilic attack
by water to displace the enzyme and generate free peptidylcitrulline [11]. (b) SDS-PAGE analysis of deiminated recombinant ovPrP. The gel shows analysis of the trypsin digestion of
untreated (control) and PAD-treated recombinant ovPrP (0.75 mg/ml) over an hour. At t=0, deiminated ovPrP showed the presence of three clear bands (labels 1, 2, and 3 on gel)
clustered between 23 and 25 kDa whereas the control samples did not. Samples were removed at timed intervals and stored at −20 °C prior to SDS-PAGE analysis and coomassie
staining.
1125D.S. Young et al. / Biochimica et Biophysica Acta 1794 (2009) 1123–1133
Fig. 2. Extracted ion chromatograms for the peptides MLGSAMSRPL and IHFGNDYEDRY. Chromatograms of the material eluting at the speciﬁc masses for the arginine-containing peptides were
collected foreachof theuntreatedcontrol andPAD-treatedsamples. Thechromatogramsshowthe%ofmodiﬁcationspresent inbands1, 2 and3 (see Fig.1b)ofmodiﬁed samples as compared toan
untreated control. Modiﬁed and unmodiﬁed peptides had a different retention time and thus the relative amount of conversion of arginine to citrullinewas estimated by the relative peak height.
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further suggesting that deimination had occurred since the loss of the
positive charge on conversion to citrulline would decrease detection
of arginine-containing peptides by the mass spectrometer.
However, several signals were still evident suggesting that not all
the arginine residues had been converted. The peak at m/z 969.72 is
1 Da more than that seen in untreated protein at 968.72 for the
peptide YRPVDRY, which would agree with one of the two arginine
residues (R167 or R171) having been deiminated; the persistence of the
second arginine residue would also explain the only slight decrease in
the intensity of the signal. Similarly, signals at m/z 1429.64 and
1592.62 suggest that deimination has occurred at R151. The signal at
m/z 1044.68 is similar to that in the untreated protein, suggesting that
modiﬁcation at R223 is less favoured.
Correlation of the chromatographic trace and the mass spectrum
allowed the ratio of modiﬁed and unmodiﬁed arginine in each of the
peptides to be estimated. These values are summarised in Table 1.
Modiﬁcation of arginyl residues was found to give a clear increase in the
retention timeof the peptides on reverse-phase chromatography,which
would be expected with the loss of charge and increase in mass and
hydrophobicity concomitant with deimination. Therefore, the relative
amount of modiﬁed and unmodiﬁed peptides can easily be visualised
from the peak heights in the ion extracted chromatograms. No evidence
of a background level of citrullination in the untreated protein was
observed in any sample. Peptides containing the arginine residues in the
N-terminal region of the protein were not distinguishable for analysis.
Because of the difﬁculty in achieving 100% mono- or di-modiﬁca-
tion under the conditions used, the mixture of treated protein rather
than separatedmono- or di-modiﬁed proteinwas investigated further.
3.2. Circular Dichroism (CD) analysis of deiminated ovPrP reveals a
β-sheet structure
The solubility of the deiminated product allowed CD spectroscopy
analysis of the samples (Fig. 3). The averaged spectra from the
deiminated sample showed a marked change in the secondary
structure. The untreated protein gave a spectrum indicative of a
predominantly α-helical secondary structure with a small amount of
β-sheet, as expected. In contrast, the deiminated protein contained
mostly β-sheet structure. (CD analysis of α-helical structures gives a
strongly positive band at 192 nm and two negative peaks at around
208–210 and 222 nm, whilst β-sheet structures give a moderate
positive peak at 198 nm and a negative peak at 215 nm.)
3.3. PK sensitivity of rec ovPrP is altered on deimination and in the
presence of copper
The protease resistance of PAD-treated rec ovPrP was investigated
in order to determine whether the modiﬁcation of arginine residues
had altered the susceptibility of the protein to PK (Fig. 4a). PK
digestion was carried out either in the presence or absence of copper
ions. In the absence of copper ions, both the untreated and deiminated
protein digested to give bands between 7 and 11 kDa. However, in the
presence of copper ions, untreated PrP was digested whereas
deiminated PrP was not.
As copper binding at the N-terminal octarepeats of PrP has been
shown to have an effect on the PK sensitivity of different forms of PrP
in several studies [23–25] the effect of copper ions on the protease
resistance of PAD-treated rec ovPrP was investigated (Fig. 4b). In the
presence of copper, the protease resistance of the deiminated protein
dramatically increased, whereas that of the untreated control was
unchanged.
3.4. PK sensitivity of deiminated protein can be restored with β-breakers
The potential of a 13-residue β-sheet breaker peptide, denoted
iPrP13 [26], which could promote the conversion of the deiminated
protein from a β-sheet conformation to a predominantly α-helical
statewas investigated (Fig. 4c). Atmillimolar concentrations of iPrP13,
the PK sensitivity of the modiﬁed protein in the presence of copper
could be restored at higher protease concentrations.
3.5. Deiminated ovPrP displays birefringence and an increased CR afﬁnity
The insoluble fraction of the rec ovPrP after PAD treatment was
pooled from several reactions and dried onto gelatin-coated slides for
analysis with CR. The white precipitate, unlike the soluble unmodiﬁed
protein, was seen to be CR-positive, and gave a characteristic apple-
green birefringence under polarised light (Fig. 5a). Interaction of CR
with amyloid in solution is known to induce a hyperchromic shift,
from amaximal absorbance around 480 nm to around 540 nm [22]. By
monitoring the change in intensity of the two absorbancemaxima, the
amount of CR bound to the PAD-treated protein was estimated
(Fig. 5b). The PAD-treated protein was found to bind more molecules
of CR than an equivalent amount of untreated protein. This
corresponds to an increased proportion of amyloid structure in the
modiﬁed protein.
3.6. Fluorescent amyloid dyes bind deiminated rec ovPrP
The ability of the dyes ANS and ThT, both used in protein folding
and amyloidogenesis studies, to bind soluble deiminated rec ovPrP
was investigated (Fig. 6). The deiminated sample demonstrated a
Table 1
The table indicates the percentage of arginine residues that are deiminated in the
tryptic peptides in each of the samples.
Peptide Percentage arginine modiﬁed
Untreated Treated 1 Treated 2 Treated 3
MLGSAMSR139PL 0 34 87 97
IHFGNDYEDR151Y 0 0 55 90
YR154ENMY 0 40 99 100
R159YPNQVY 0 18 89 98
YR167PVDR171Y 0 mono/0 di 49/9 59/29 4/95
QR223ESQAYY 0 6 16 23
The percentage modiﬁcation was calculated from the peak heights in the extracted-ion
chromatograms of the respective monoisotopic peptide molecular ions. The peptide
YRPVDRY contained two arginine residues, and the relative amount of mono- and di-
modiﬁcation is indicated.
Fig. 3. Secondary structural analysis of deiminated rec ovPrP by Circular Dichroism
(CD). Unmodiﬁed (thin line, control) and PAD-treated (bold line) rec ovPrP were
analysed by CD from 250 to 190 nm. Spectra were normalised for protein concentration
and amino acid length (208 nm for rec ovPrP) to give a reading in mean residue weight
ellipticity ([θmrw], degrees cm2 dmol−1). The unmodiﬁed protein gave a spectrum
indicative of a predominantly α-helix with 20% β-sheet whereas the deiminated
protein had a predicted 40% of β-sheet, as estimated using JFIT (JASCO) software.
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markedly stronger ﬂuorescent signal compared to the control when
incubated with ANS, increase in ANS ﬂuorescence was observed to
follow a linear trend with both untreated (r2=1.00) and PAD-treated
(r2=0.98) samples.
Both the untreated and deiminated samples gave ﬂuorescent
signals of the same order of magnitude with ThT, with similar
responses. However, the ﬂuorescence of the deiminated samples was
consistently stronger than that of the untreated sample. Therefore,
under these experimental conditions, the afﬁnity of the dye for the
modiﬁed protein was only marginally increased and was not
statistically signiﬁcant (P=0.6). Different solvent conditions were
tested, with little apparent difference (data not shown).
3.7. Templating ability of deiminated recombinant ovine rec ovPrP
The templating ability of the deiminated protein to promote a
change in conformation to untreated protein was investigated. The
deiminated protein was diluted back into unmodiﬁed rec ovPrP and
incubated, before aliquots were assessed for PK resistance to ascertain
whether in vitro conversion had occurred. Incubation of the untreated
sample overnight with more untreated rec ovPrP had shown some
increase in protease resistance of the sample. However, when
deiminated protein was incubated with the untreated rec ovPrP, a
more signiﬁcant increase in the protease resistance was observed
(Fig. 7a and b). Furthermore, this increased afﬁnity for CR could be
templated onto unmodiﬁed protein. Untreated rec ovPrP that had
been incubated with PAD-treated protein overnight displayed an
increased afﬁnity for CR compared to untreated protein incubated
with the untreated control (data not shown).
To determine whether the nature of the templated acquisition of
PK resistance might be mediated through the transfer of an altered
secondary structure, samples of PAD-treated rec ovPrPwere incubated
with untreated rec ovPrP and the structure assessed by FTIR spectro-
scopy after set time intervals (Fig. 7c). After 6 h, little change in the
secondary structure of the protein was observed. However, after 12 h
incubation, a shoulder appeared in the amide I spectrum at
approximately 1620 cm−1, indicating the presence of increased β-
sheet structure [27]. This was enhanced further on incubation for 24 h.
The intensity of the signal at 1620 cm−1 in the deconvoluted spectra
was 11.2 after 6 h,12.9 after 12 h, and 23.6 after 24 h. This suggests that
Fig. 4. Deimination of rec ovPrP confers PK resistance in the presence of copper. (a) PAD-treated ovPrP in the presence of Cu2+ was incubated either with 50% acetonitrile (untreated
control) or with 50% acetonitrile containing iPrP13 (mM) for 2 h with shaking at room temperature. Untreated (control) and PAD-modiﬁed recombinant ovPrP (0.75 mg/ml) were
incubated with proteinase K at the dilutions shown for 1 h at 37 °C with shaking, and the reaction stopped by addition of PMSF. The samples were then analysed by SDS-PAGE and
Coomassie staining. (b) Proteinase K resistance of PAD-treated recombinant ovPrP in the presence of copper ions. Control and PAD-treated rec ovPrP (0.75 mg/ml) were incubated
with Proteinase K at the dilutions shown in the presence of copper sulphate (1 mM) for 1 h at 37 °C with shaking, and the reaction stopped by addition of PMSF. The samples were
then analysed by SDS-PAGE and coomassie staining. (c) Restoration of protease sensitivity to deiminated rec ovPrP on incubationwith a β-breaker peptide. PAD-treated rec ovPrPwas
incubated with 50% acetonitrile as a control, and 50 % acetonitrile containing iPrP13 (1 mM) for 2 h with shaking at room temperature. The samples were then assayed for PK
resistance in the presence of copper(II) sulphate (1 mM) as described above, and the results assayed by SDS-PAGE and Coomassie staining.
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themechanism for templating the properties of PAD-treated rec ovPrP
onto untreated rec ovPrP involves the transfer and acquisition of a
structure with increased β-sheet content.
4. Discussion
These observations that deimination of rec ovPrP leads to the rapid
acquisition of PrPSc-like characteristics have provided some interest-
ing and novel insights into the possible impact and importance of
arginine modiﬁcation on PrP structure. The recent report regarding
the accumulation of citrullinated proteins in the brains of scrapie-
infected mice makes this discovery even more pertinent [28]. Arginyl
residues in different locations in PrP might be expected to have a
different impact on the protein structure and functionwhenmodiﬁed.
The investigation into deimination of prion protein was prompted by
the brief mention in several references of an unknown modiﬁcation
occurring with a low incidence in the N-terminus of PrP [17–18].
Modiﬁcation in the latter case was seen in vivo therefore, but only in
heterogeneous samples. This could suggest a possible regulatory role
for the modiﬁcation, or a low level of aberrant modiﬁcation caused by
altered enzyme activity in the cell. Deimination of positive arginyl
residues in this region (R27, R40 and R51 in rec ovPrP) to neutral
citrulline could be expected to alter the copper-binding afﬁnity of the
octarepeats, and so disrupt the native function of PrP. Whether this
would be a means of regulating PrP activity, or simply be an indicator
of aberrant PAD activity is not clear.
The N-terminus of PrP has also been suggested to play a role in
trafﬁcking of the protein to the cell surface, speciﬁcally to lipid rafts
[29–30]. N-terminal deletions were found to disrupt internalisation
and increase the cellular half-life of PrP, and could be restored by
addition of regions distinct from the copper-binding elements [31]. If
arginyl residues are important in the recognition of the N-terminus
during trafﬁcking, or for the lipid association itself, it is possible that
modiﬁcation of these would abrogate the internalisation and allow
pathogenic forms of the protein to persist for longer, increasing the
risk of transmission of the infectious characteristics.
Several lines of evidence implicate helix 1 as playing a signiﬁcant
role in the structure of PrPC and in disease propagation. Helix 1 is
believed to be stabilised by salt-bridges between two aspartate–
arginine pairs; D147-R151 and D150-R154 in rec ovPrP. Deimination of
such key arginyl residues could interfere with these salt-bridge
interactions and would also be expected to destabilise the native fold.
The helix 1 region has also been implicated in dimerisation of PrP
[32,33]. This could suggest a role for deimination of helix 1 arginyl
residues in reducing the energy barrier to dimerisation and promoting
initial aggregate formation. Within Helix 1, R151 appeared less
accessible to modiﬁcation by PAD than R154, and was not modiﬁed
at all in the PAD-treated protein of lowest apparent molecular mass.
Fig. 5. PAD-treated rec ovPrP shows birefringence and Congo Red afﬁnity. (a) Representative images of PAD-treated rec ovPrP after CR staining. The insoluble fraction of the
deimination reactionwas dried on gelatin-coated slides and stained with CR for the presence of amyloid ﬁbrils. The left and right panels show the stained protein under normal and
polarised light respectively. Magniﬁcation is 40×. (b) Quantiﬁcation of the CR afﬁnity of the modiﬁed protein. Samples of untreated and PAD-treated ovPrP were corrected for
concentration and incubated with CR in potassium phosphate buffer solution (0.1 M, pH 7.4) with sodium chloride (150 mM), for 30 min at room temperature. The absorbance was
monitored at 540 and 477 nmwith a baseline correction taken at 600 nm, and the number of moles of dye bound to the protein calculated using the method of Klunk et al. [22]. The
ﬁgure shows the results from 3 independent assays.
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R151 was modiﬁed in the protein of increased apparent molecular
mass and was not recognised by the antibody 6H4 (data not shown)
[34]. This would suggest that this residue is important in the epitope
recognised by 6H4. Both R151 and R154 are also in a helical region of
the protein in close proximity to glutamate residues, and are thought
to be involved in salt-bridge stabilisation of the structure [35].
Therefore, these residuesmight not be expected to be readilymodiﬁed
by PAD. However, helix 1 is also thought to be structurally plastic, and
modiﬁcation of other residues in the protein might induce structural
rearrangement around helix 1 that increases the rate of modiﬁcation
of R151 and R154. This is suggested by the poormodiﬁcation of R151 in
the population of protein with the least modiﬁcation.
The peptide YRPVDRY contained two arginine residues R167 and
R171, and thus the relative amounts ofmono- and di-modiﬁcation could
be estimated. R167 is thought to becomemore exposed to the solvent on
the conformational change from PrPC to PrPSc [35]. The NMR structures
of rec ovPrP from various species indicate that arginine residues
equivalent to R167 are the least solvent exposed arginine residues
(Table 1). While deimination of both these residues appear to happen
readily, it was not possible to determine the different reactivities of the
two residues, although the fragmentation spectrum of the mono-
modiﬁed peptide showed evidence of modiﬁcation of both arginine
residues i.e. each arginine residue can be independently modiﬁed.
By mass spectrometry, each peptide showed an increase in
arginine modiﬁcation which correlated with the increased apparent
molecular mass (decreased electrophoretic mobility) of the sample.
The extent of modiﬁcationwas high for most residues (at least 90% for
six of the seven arginine residues analysed, in the band of highest
apparent molecular mass), although the C-terminal residue R223 was
less well modiﬁed. Although thought to be highly exposed to the
solvent, this residue is within a putativeα-helical region and followed
by a glutamate residue, and previous studies have shown such an
environment not to favour deimination by PAD [3].
Because of the difﬁculty in achieving 100% mono- or di-modiﬁed
arginine residues in the protein, studies were carried out on the
reactionmixture of treated protein. However, it would be of interest to
carry out further studies to determine conditions which allow for
partial or total modiﬁcation of arginine residues and to separate out
the mono- and di- modiﬁed proteins for further structural studies. By
doing this, it should be possible to identify the pivotal role of deﬁned
arginine residues on the conformation of prion protein.
The CD analysis of deiminated rec ovPrP revealed a β-sheet structure
and this characteristic has been used previously to monitor changes in
PrP conformation under various conditions [36–39]. Although the
protein sample could not be modiﬁed to homogeneity under the
conditions used in this study, the results from the CD spectroscopy
showed a change to a predominantly β-sheet conformation. CD
spectroscopy of deiminated ﬁlaggrin (predominantly β-turn secondary
structure) and trichohyalin (α-helical) has shown previously that the
protein secondary structure can be disrupted by deimination, but in the
cases examined so far, the structure has been lost rather than converted
[3]. This changewas shown tobeanalogous to the addition of urea, and it
was suggested that the ureido group of citrulline was acting in a similar
manner. Thus, in the case of prion protein, the presence of the ureido
group on the citrulline may act to destabilise the native fold enough to
allow the protein to partially unfold and so adopt a more stable scrapie-
associated conformation with a higher β-sheet content.
Protease resistance has long been established as a key character-
istic by which to distinguish PrPC and PrPSc [40–43], where PrPSc is
distinguished by the presence of a 17 kDa protease-resistant core.
However, despite an apparent conformational change in the protein as
determined by CD spectroscopy, the deiminated protein is still largely
susceptible to PK digestion, except in the presence of copper (Fig. 1b).
The fact that it was the full-length protein that was PK-resistant is of
interest as, in general, PrPSc is characterized by a PK-resistant core of
17 kDa. This ﬁnding may be explained by the decrease in the pI of the
deiminated protein altering the interaction of copper ions and PrP;
whether this causes deiminated rec ovPrP to adopt a conformation
less accessible to proteinase K, or is otherwise more stable, is unclear.
The fact that the untreated PrP was still sensitive to PK in the presence
of copper ions either argues against the recent ﬁnding that PK activity
can be inhibited by copper ions or was carried out at a concentration
that was not inhibitory [44]. Increased PK resistance of rec ovPrP in the
presence of manganese ions has been reported previously, although
the authors only mention a possible alteration in secondary structure
as the cause [45,46]. Therefore, it seems possible that the creation of
ureido groups on citrulline within the protein may create alternative
copper complexation sites. Alternatively, the ureido groups may
destabilise the protein structure and reveal hidden or cryptic sites able
to bind copper ions. An internal copper-binding site was found in
recombinant human PrP (huPrP), formed by histidines 96 and 111,
with a similar afﬁnity to that of the octarepeat region [47]. It may be
that destabilisation of the protein structure by the presence of
citrulline residues alters the accessibility and/or afﬁnity of this site.
The same authors also found that copper bound to the reduced β-
sheet conformation of the recombinant huPrP with a marginally
higher afﬁnity than the oxidised α-helical form. This would correlate
with our ﬁnding that the deiminated rec ovPrP, has an increased PK
resistance in the presence of copper. In addition, the fact that PK
sensitivity of deiminated protein could be restored with β-breakers
correlates with the work of Soto et al. [26]. The latter found that
incubation of protease-resistant PrP with iPrP13 restored the PK
sensitivity by promoting the conversion of the protein back to its α-
helical state from the resistant β-sheet conformation. Alternatively, it
may be that the β-breaker peptide binds copper more efﬁciently and
that this decrease in copper ions allows reactivation of the PK enzyme.
Fig. 6. Binding of ﬂuorescent dyes to deiminated rec ovPrP. Demonstration of (a) ANS
and (b) ThT binding by samples containing deiminated rec ovPrP. Graphs showing data
taken from six and eight samples from two batches of protein respectively, error bars
correspond to one standard deviation.
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Fig. 7. (a) In vitro conversion of rec ovPrP monitored by the acquisition of PK resistance. Samples of untreated control (left panel) and PAD-treated (right panel) rec ovPrP were diluted (1:20
sample:stock protein) into the stock ovPrP (1.5mg/ml) and incubated at room temperature overnight,with shaking. The sampleswere assayed for PK resistance in the presence of copper and
analysed by SDS-PAGE and coomassie staining. (b)Templating of PK resistance in the presence of copper. Samples of PAD-treated rec ovPrP were diluted (1:20 sample:stock protein) into the
stock rec ovPrP and incubated for 12 (triangles) and 24h (squares) in thepresence (black symbols) and absence (white symbols) of copper (500 μM). Sampleswere then assayed for protease
resistance as described previously, and the relative level of protein at 23 kDawas assessed by densitometry.▵— incubation for 12 h in the absence of copper;□— incubation for 24 h in the
absenceof copper;▴— incubation for12h in thepresenceof copper;■— incubation for24h in thepresenceof copper.Dashed lines represent the levels ofprotein after0h inthe absence (light
line) and presence (bold line) of copper. Error bars depict the standard deviation for 2 independent samples. (c) FTIR spectroscopy of untreated rec ovPrP after incubation in the presence of
deiminated rec ovPrP seed. PAD-treated rec ovPrPwas diluted 20-fold into untreated rec ovPrP in the absence of copper and incubated for 0, 6,12 and 24 h at 37 °C. Spectra show Fourier self-
deconvolutedabsorbance spectraofuntreated templated recovPrPsamplesat t=0(○), t=6h(▴), t=12h(□) and t=24h(O). Similar changesonstorageofuntreatedproteinwerenot seen.
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However, the fact that in our study untreated protein remained PK-
sensitive in the presence of copper ions argues against this.
The increased afﬁnityof deiminated rec ovPrP for the amyloid-speciﬁc
dye Congo red was interesting. Although the exact mechanism of CR
binding to amyloid is not known, studies using PrPC suggested that, as
well as the planar aromatic aspect of the dye, thepresence of the sulphate
groups are vital to form the electrostatic interactions required for binding
of the dye to the protein [48,49]. Therefore, it might be expected that
deimination, and the loss of positive charge,might decrease the afﬁnity of
the dye for the protein. However, the presence of birefringence implies
there is perhaps amore suprastructural or conformational reason behind
the altered dye interaction with the modiﬁed protein. In addition,
ﬂuorescent amyloid dyes also bound more strongly to deiminated rec
ovPrP indicating an increasedproportionof exposedhydrophobic regions
in the modiﬁed protein. This would correspond with the conformational
changes indicated by the apparent shift to a predominately β-sheet
conformation, which would be expected to expose areas of the protein
buried in the native conﬁguration.
A key ﬁnding of these studies was the fact that deiminated rec
ovPrP could template its change in PK sensitivity to unmodiﬁed rec
ovPrP. As residual PAD activity is inhibited, how this in vitro
conversion might occur is intriguing. If it is the conformation that is
crucial for the increased protease resistance of rec ovPrP in the
presence of copper, then it is possible that the conformation of the
deiminated rec ovPrP can act as a template for the conversion of the
unmodiﬁed protein. The fact that the protein remains predominantly
monomeric, suggests that any templating effect would not necessarily
be similar to themechanism proposed for amyloid ﬁbril formation and
growth. In the future, discrimination between the added deiminated
seed and unmodiﬁed protein could be carried out in studies by
western blotting using an anti-citrulline antibody. In this instance,
however, we relied on the fact that deiminated protein separated as
three bands on SDS-PAGE. Detection of the deiminated seed prior to
the experiment was negligible as shown in the right hand panel in
Fig. 7a. This suggested that the PK resistance observed in the
templating experiment must be due to the templating effect of the
added seed rather than PK resistance of any deiminated seed.
Combined, this evidence suggests that post-translational modiﬁ-
cation may have the potential to play a signiﬁcant role in the initiation
or propagation of prion disease. Whilst deimination could form the
basis of future studies into possible causes, treatment or identiﬁcation
of novel biomarkers of prion diseases, the fact that its presence causes
a change in protein conformation is of interest in itself. Recently, we
have also shown that production of post-translational modiﬁcations
within recombinant prion protein due to oxidative stress conditions
can have a similar effect on conformation [2]. The fact that the
residues involved are different but lie within a similar area of the
molecule supports observations on the critical role of charged residues
in the helix 1 region in changing prion protein's conformation [50].
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